<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999713</url>
  </required_header>
  <id_info>
    <org_study_id>1R01FD003410-01</org_study_id>
    <secondary_id>R01FD003410-01A1</secondary_id>
    <nct_id>NCT00999713</nct_id>
  </id_info>
  <brief_title>CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients</brief_title>
  <acronym>CALIPSO</acronym>
  <official_title>A Phase 3 Trial of Calfactant for ALI in Pediatric Leukemia and HSCT Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute lung injury (ALI) is a common, life-threatening complication among pediatric leukemia
      and lymphoma and hematopoietic stem cell transplant (HSCT) recipients. Although these
      children represent a relatively small and unique patient population, they account for the
      largest proportion of deaths of all pediatric diseases. The long-term goal of this project is
      to improve outcomes among these patients. Recently, the intratracheal administration of
      calfactant has resulted in decreased mortality among children with ALI including promising
      results among children with cancer and following HSCT. Consequently, the primary specific aim
      of this study is to assess the effect of calfactant on intensive care (PICU) survival among
      pediatric leukemia and lymphoma and HSCT patients with ALI. Secondary aims include assessment
      of the effect of calfactant on oxygenation and on the length of mechanical ventilation, PICU
      stay, and hospital stay. Calfactant therapy has been found to be of benefit in acute lung
      injury in the overall pediatric population by improving oxygenation and decreasing mortality.
      These findings, in conjunction with recent subgroup analysis in which calfactant therapy
      appeared to improve outcomes in immunocompromised children provide the rationale for
      assessing calfactant therapy in this patient population.

      Funding Source - FDA Office of Orphan Products Development (OOPD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality at the Time of Pediatric Intensive Care Unit (PICU) Discharge</measure>
    <time_frame>Admission to PICU discharge, up to 120 days</time_frame>
    <description>Overall mortality rate from admission to PICU discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator Free Days (VFDs)</measure>
    <time_frame>60 days after study enrollment</time_frame>
    <description>Number of days the patient is alive and off of the ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Duration of Stay Required</measure>
    <time_frame>Admission to discharge, up to 120 days</time_frame>
    <description>Length of stay (LOS) ,measured in days, from admission to PICU discharge and admission to hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxygenation: First Intervention</measure>
    <time_frame>48 hours after enrollment, up to 12 hours after each intervention</time_frame>
    <description>The Oxygenation Index after the first intervention is calculated as the fraction of inspired oxygen, in percent, times the mean airway pressure, in mmHg, divided by the partial pressure of oxygen in arterial blood, in mmHg. Lower values are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxygenation: Second Intervention</measure>
    <time_frame>48 hours after enrollment, up to 12 hours after each intervention</time_frame>
    <description>The Oxygenation Index after the second intervention (if applicable) is calculated as the fraction of inspired oxygen, in percent, times the mean airway pressure, in mmHg, divided by the partial pressure of oxygen in arterial blood, in mmHg. Lower values are better.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Acute Lung Injury</condition>
  <arm_group>
    <arm_group_label>Calfactant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endotracheal calfactant administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (air)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Endotracheal air administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calfactant</intervention_name>
    <description>Endotracheal calfactant, up to 3 doses if subject qualifies</description>
    <arm_group_label>Calfactant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Air placebo</intervention_name>
    <description>Endotracheal air administration</description>
    <arm_group_label>Placebo (air)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must meet criteria for acute lung injury

               -  Intubated, mechanically ventilated, with respiratory failure secondary to
                  diffuse, bilateral parenchymal lung disease (as judged by chest x-ray).

               -  Oxygenation index (OI) &gt; 13, but &lt; 37, for two consecutive blood gases which
                  should be separated by at least one hour within 48 hours of the initiation of
                  mechanical ventilation.

               -  Arterial catheter placement

               -  Parental informed consent

          2. Patients must have a diagnosis of leukemia/lymphoma undergoing active treatment or
             following HSCT for any indication. Leukemia/lymphoma will be defined according to the
             National Cancer Institute Surveillance Epidemiology and End Results Collaborative
             Staging Manual including those conditions defined as borderline such as
             myelodysplastic syndromes. All forms of HSCT will be eligible, allogeneic as well as
             autologous.

        Exclusion Criteria:

          1. Clinical diagnosis of congestive heart failure and/or pulmonary capillary wedge
             pressure &gt;15 mmHg, or uncorrected congenital heart disease.

          2. Glasgow Coma Score &lt; 8 (prior to respiratory failure).

          3. Pre-existing limitations on care options, (Do Not Attempt Resuscitation Orders, etc).

          4. Patients with impending death from another disease.

          5. Patients moribund or with other organ failure at possible randomization:

               -  hypotension unresponsive to treatment (mean BP &lt; 60 or &lt; 5th % for age),

               -  persistent cardiac tachyarrhythmia &gt;150/minute, or persistent bradyarrythmia &lt;
                  50/minute, or age appropriate criteria for younger children,

               -  metabolic acidosis &gt; - 10 milliequivalent (mEq)/L for more than 2 hours,

               -  persistent arterial oxygen desaturation, arterial partial pressure of oxygen
                  (PaO2) &lt; 50 or oxygen saturation (SaO2) saturation &lt; 80%,

               -  hyperkalemia, serum K+ &gt; 6.5 plus widening of QRS complex on EKG (QRS complex
                  corresponds to the depolarization of the right and left ventricles of the heart).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal J Thomas, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert F Tamburro, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Fareri Children's Hospital</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tamburro RF, Thomas NJ, Pon S, Jacobs BR, Dicarlo JV, Markovitz BP, Jefferson LS, Willson DF; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Post hoc analysis of calfactant use in immunocompromised children with acute lung injury: Impact and feasibility of further clinical trials. Pediatr Crit Care Med. 2008 Sep;9(5):459-64. doi: 10.1097/PCC.0b013e3181849bec.</citation>
    <PMID>18679142</PMID>
  </reference>
  <reference>
    <citation>Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, Jacobs BR, Jefferson LS, Conaway MR, Egan EA; Pediatric Acute Lung Injury and Sepsis Investigators. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005 Jan 26;293(4):470-6. Erratum in: JAMA. 2005 Aug 24;294(8):900.</citation>
    <PMID>15671432</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2009</study_first_submitted>
  <study_first_submitted_qc>October 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2009</study_first_posted>
  <results_first_submitted>January 19, 2018</results_first_submitted>
  <results_first_submitted_qc>February 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2018</results_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Neal Thomas</investigator_full_name>
    <investigator_title>Neal J. Thomas, MD, Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</investigator_title>
  </responsible_party>
  <keyword>Acute Lung Injury</keyword>
  <keyword>Cancer</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calfactant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Calfactant</title>
          <description>Endotracheal calfactant administration
Calfactant: Endotracheal calfactant, up to 3 doses if subject qualifies</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Air)</title>
          <description>Endotracheal air administration
Air placebo: Endotracheal air administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calfactant</title>
          <description>Endotracheal calfactant administration
Calfactant: Endotracheal calfactant, up to 3 doses if subject qualifies</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Air)</title>
          <description>Endotracheal air administration
Air placebo: Endotracheal air administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All-cause Mortality at the Time of Pediatric Intensive Care Unit (PICU) Discharge</title>
        <description>Overall mortality rate from admission to PICU discharge</description>
        <time_frame>Admission to PICU discharge, up to 120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calfactant</title>
            <description>Endotracheal calfactant administration
Calfactant: Endotracheal calfactant, up to 3 doses if subject qualifies</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Air)</title>
            <description>Endotracheal air administration
Air placebo: Endotracheal air administration</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality at the Time of Pediatric Intensive Care Unit (PICU) Discharge</title>
          <description>Overall mortality rate from admission to PICU discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Free Days (VFDs)</title>
        <description>Number of days the patient is alive and off of the ventilator</description>
        <time_frame>60 days after study enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calfactant</title>
            <description>Endotracheal calfactant administration
Calfactant: Endotracheal calfactant, up to 3 doses if subject qualifies</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Air)</title>
            <description>Endotracheal air administration
Air placebo: Endotracheal air administration</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Free Days (VFDs)</title>
          <description>Number of days the patient is alive and off of the ventilator</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="21.02"/>
                    <measurement group_id="O2" value="5.40" lower_limit="0" upper_limit="17.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Duration of Stay Required</title>
        <description>Length of stay (LOS) ,measured in days, from admission to PICU discharge and admission to hospital discharge.</description>
        <time_frame>Admission to discharge, up to 120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calfactant</title>
            <description>Endotracheal calfactant administration
Calfactant: Endotracheal calfactant, up to 3 doses if subject qualifies</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Air)</title>
            <description>Endotracheal air administration
Air placebo: Endotracheal air administration</description>
          </group>
        </group_list>
        <measure>
          <title>Total Duration of Stay Required</title>
          <description>Length of stay (LOS) ,measured in days, from admission to PICU discharge and admission to hospital discharge.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LOS from admission to PICU discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="8" upper_limit="29.5"/>
                    <measurement group_id="O2" value="21" lower_limit="12.5" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOS from admission to hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="17.5" upper_limit="95.5"/>
                    <measurement group_id="O2" value="65" lower_limit="21" upper_limit="107.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oxygenation: First Intervention</title>
        <description>The Oxygenation Index after the first intervention is calculated as the fraction of inspired oxygen, in percent, times the mean airway pressure, in mmHg, divided by the partial pressure of oxygen in arterial blood, in mmHg. Lower values are better.</description>
        <time_frame>48 hours after enrollment, up to 12 hours after each intervention</time_frame>
        <population>Total number of subjects analyzed at each measurement fluctuates due to arterial blood gas testing not being ordered at the appropriate time (i.e., subjects missing a test at a specific time point since the frequency of these tests in this study are not standard of care).</population>
        <group_list>
          <group group_id="O1">
            <title>Calfactant</title>
            <description>Endotracheal calfactant administration
Calfactant: Endotracheal calfactant, up to 3 doses if subject qualifies</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Air)</title>
            <description>Endotracheal air administration
Air placebo: Endotracheal air administration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxygenation: First Intervention</title>
          <description>The Oxygenation Index after the first intervention is calculated as the fraction of inspired oxygen, in percent, times the mean airway pressure, in mmHg, divided by the partial pressure of oxygen in arterial blood, in mmHg. Lower values are better.</description>
          <population>Total number of subjects analyzed at each measurement fluctuates due to arterial blood gas testing not being ordered at the appropriate time (i.e., subjects missing a test at a specific time point since the frequency of these tests in this study are not standard of care).</population>
          <units>index number</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Intervention: Hour 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.30178397" lower_limit="14.8899734" upper_limit="22.49535894"/>
                    <measurement group_id="O2" value="20.59720208" lower_limit="16.21205422" upper_limit="26.16847488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Intervention: Hour 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.10723481" lower_limit="12.40927173" upper_limit="20.9071909"/>
                    <measurement group_id="O2" value="19.25708144" lower_limit="13.98618037" upper_limit="26.51440036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Intervention: Hour 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.79254257" lower_limit="11.76126752" upper_limit="18.60507937"/>
                    <measurement group_id="O2" value="16.80523147" lower_limit="12.85367235" upper_limit="21.97160447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Intervention: Hour 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.06208571" lower_limit="13.03988505" upper_limit="22.32494901"/>
                    <measurement group_id="O2" value="16.42411116" lower_limit="11.98559242" upper_limit="22.50630741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oxygenation: Second Intervention</title>
        <description>The Oxygenation Index after the second intervention (if applicable) is calculated as the fraction of inspired oxygen, in percent, times the mean airway pressure, in mmHg, divided by the partial pressure of oxygen in arterial blood, in mmHg. Lower values are better.</description>
        <time_frame>48 hours after enrollment, up to 12 hours after each intervention</time_frame>
        <population>Total number of subjects analyzed at each measurement fluctuates due to arterial blood gas testing not being ordered at the appropriate time (i.e., subjects missing a test at a specific time point since the frequency of these tests in this study are not standard of care).</population>
        <group_list>
          <group group_id="O1">
            <title>Calfactant</title>
            <description>Endotracheal calfactant administration
Calfactant: Endotracheal calfactant, up to 3 doses if subject qualifies</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Air)</title>
            <description>Endotracheal air administration
Air placebo: Endotracheal air administration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxygenation: Second Intervention</title>
          <description>The Oxygenation Index after the second intervention (if applicable) is calculated as the fraction of inspired oxygen, in percent, times the mean airway pressure, in mmHg, divided by the partial pressure of oxygen in arterial blood, in mmHg. Lower values are better.</description>
          <population>Total number of subjects analyzed at each measurement fluctuates due to arterial blood gas testing not being ordered at the appropriate time (i.e., subjects missing a test at a specific time point since the frequency of these tests in this study are not standard of care).</population>
          <units>index number</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Second Intervention: Hour 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.65261779" lower_limit="10.74981818" upper_limit="22.79149651"/>
                    <measurement group_id="O2" value="15.05105738" lower_limit="10.19615508" upper_limit="22.21762286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Intervention: Hour 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.28116857" lower_limit="15.40809906" upper_limit="29.39286242"/>
                    <measurement group_id="O2" value="14.68059885" lower_limit="10.36992308" upper_limit="20.78318046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Intervention: Hour 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.47108142" lower_limit="13.41337922" upper_limit="22.75628541"/>
                    <measurement group_id="O2" value="15.40251337" lower_limit="11.60739802" upper_limit="20.43846672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Intervention: Hour 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.26865232" lower_limit="12.65514101" upper_limit="23.56404822"/>
                    <measurement group_id="O2" value="14.83842164" lower_limit="10.66746181" upper_limit="20.64021983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Calfactant</title>
          <description>Endotracheal calfactant administration
Calfactant: Endotracheal calfactant, up to 3 doses if subject qualifies</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Air)</title>
          <description>Endotracheal air administration
Air placebo: Endotracheal air administration</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peri-dosing hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Peri-dosing Hypoxia or Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pneumomediatinum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neal J. Thomas, M.D.</name_or_title>
      <organization>Penn State College of Medicine</organization>
      <phone>717-531-5337</phone>
      <email>nthomas@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

